Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular Lymphoma

Abstract

Objectives: The randomized phase 3 PRIMA trial established that 2 years of rituximab maintenance therapy after attaining disease response to immunochemotherapy as first-line treatment of follicular lymphoma, reduced the risk of disease progression, compared with observation, without adversely affecting patientreported quality of life (QoL). We now report additional analyses of symptom burden and toxicity. Methods: Symptom burden was measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items. The proportion of patients with worsening, no change, or improvement in symptoms from maintenance baseline was compared between rituximab maint..